Status:
RECRUITING
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Lead Sponsor:
The George Institute
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or comb...
Detailed Description
Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early d...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Known chronic kidney disease from any cause (eGFR ≥25 mL/min/1.73m2)
- Currently receiving standard of care treatment according to treating physician
- Eligible for randomisation in at least one recruiting domain-specific appendix
- Participant and treating physician are willing and able to perform trial procedures
Exclusion
- Planned to commence kidney replacement therapy or kidney transplant surgery in next 6 months
- Life expectancy less than 6 months
Key Trial Info
Start Date :
September 4 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2029
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT06058585
Start Date
September 4 2024
End Date
March 31 2029
Last Update
December 15 2025
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
The Canberra Hospital
Garran, Australian Capital Territory, Australia, 2605
2
Nepean Blue Mountains Local Health District
Kingswood, New South Wales, Australia, 2747
3
St George Hospital
Kogarah, New South Wales, Australia, 2217
4
John Hunter Hospital
New Lambton Heights, New South Wales, Australia, 2305